.05 Dec | Josep Carreras Leukaemia Research Institute | BadalonaYour mission The Josep Carreras Leukemia Research Institute (IJC) is a comprehensive cancer research center dedicated to researching and promoting innovation in the epidemiological, preventive, clinical, translational and basic aspects of leukemia and other hematological malignancies, with the objective end of finding a cure for these diseases. It was created in 2010, and since then, it has experienced exponential growth. The IJC is also part of the network of Research Centers of Excellence of Catalonia (CERCA) and was accredited as a Severo Ochoa Center of Excellence by the Ministry of Science, Innovation and Universities in 2024.Since 2018, the Institute has also been accredited by the Scientific Foundation of the Spanish Association Against Cancer (FCAECC). In addition, the IJC is one of the centers integrated into the accreditation of the Germans Trias i Pujol Research Institute (IGTP) as an Accredited Health Research Institute (IIS) by the Health Institute Charles III (ISCIII). The IJC main headquarters is located within the Can Ruti Biomedical Campus, together with other leading biomedical institutions, providing direct access to cutting-edge scientific and technological facilities, as well as complementary community services. The IJC has six headquarters integrated into reference hospitals: Hospital Germans Trias i Pujol, Hospital Clínic, Hospital Sant Pau, Hospital Trueta, Hospital del Mar and Hospital San Joan de Déu. This facilitates close collaboration between basic and clinical researchers, fostering translational research that integrates basic science with clinical practice in clinical settings.We are seeking a LABORATORY TECHNICIAN for our institute.RESEARCH DESCRIPTIONThe main goal of the Stem cell biology, developmental leukemia and immunotherapy, led by Dr. Pablo Menéndez, is to investigate and understand the pathogenic mechanisms and cell-of-origin of pediatric leukemias and developing novel adoptive immunocellular therapies based on the use of CAR T-cells. Our group is interested in understanding the cellular origin, etiology and pathogenesis of childhood leukemia. We aim to ascertain the cell in which mutations occur and we strive to discover which cells are responsible for triggering relapses. Furthermore, we work to identify new therapeutic targets and develop more targeted, less toxic therapies. To achieve this, our laboratory uses various approaches, including genetic studies, epigenetic techniques and animal models, as well as adoptive cell immunotherapy tools.This contract is linked to the project PRYGN234975MENE, Next generation, off-the-shelf, CD1a/CCR9-directed dual CAR immunotherapy for relapse/refractory T-cell acute lymphoblastic leukemia.MAIN RESPONSIBILITIESMouse colony managing and breeding of immunodeficient colony (including NSG and NSGS strains)